The network of associations Childhood Cancer International-Europe (CCI-Europe) hopes that the new pharmaceutical legislation (see EUROPE B13152A35) will facilitate the development and eventual entry onto the European market of specific treatments for childhood cancers, which often represent very small markets.
In an interview on Wednesday 12 April, Delphine Heenen, founder of the CCI member KickCancer, welcomed elements that could be included in the package, such as the “mechanism of...